Lin Patrick 4
4 · Processa Pharmaceuticals, Inc. · Filed May 19, 2026
Research Summary
AI-generated summary of this filing
Processa (PCSA) Chief Business Officer Lin Patrick Buys 1,369 Shares
What Happened
Lin Patrick, Chief Business & Strategy Officer at Processa Pharmaceuticals (PCSA), purchased 1,369 shares in an open‑market transaction on May 15, 2026. The shares were acquired at $2.97 per share for a total of about $4,066. This was a straight purchase (transaction code P), which is a direct insider buy rather than a sale or option exercise.
Key Details
- Transaction date: 2026-05-15 (open market purchase)
- Price and amount: 1,369 shares at $2.97 each; total ≈ $4,066
- Transaction code: P (purchase)
- Shares owned after transaction: not disclosed in this filing
- Timeliness: Filed on 2026-05-19 (report covers 2026-05-15); filing date appears timely under standard Form 4 rules
- Footnote: Corrects an immaterial error in a prior Form 4 (filed May 1, 2026) — the April 30, 2026 purchase price was $2.71 (not $2.69), reducing that prior purchase by 11 shares
Context
Purchases by company officers are often viewed as a more informative signal than sales because they involve personal cash outlay; this filing documents a modest open‑market buy. No 10b5‑1 plan, option exercise, gift, or tax withholding is reported in this Form 4.
Insider Transaction Report
- Purchase
Common Stock
[F1]2026-05-15$2.97/sh+1,369$4,066→ 7,594 total
- 1,740(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 11 shares.